Anticancer activity of the iron facilitator LS081

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Li, Zhen ^a   Tanaka, Hiroki ^a   Galiano, Floyd ^a   Glass, Jonathan ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCEIN; CHELATING AGENT; FERRITIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LS 081; REACTIVE OXYGEN METABOLITE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DRUG DERIVATIVE; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HYDRAZONE DERIVATIVE; IRON; NICOTINAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLONOGENESIS; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; IRON TRANSPORT; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FERRITINS; HUMANS; HYDRAZONES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; NIACINAMIDE; REACTIVE OXYGEN SPECIES;

EID: 79953172279     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-34     Document Type: Article

References (48)

1. Iron and copper metabolism. M Arredondo MT Ñez, Molecular Aspects of Medicine 2005 26 4-5 313 327 10.1016/j.mam.2005.07.010 16112186 (Pubitemid 41225355)
2. Iron regulatory proteins and the molecular control of mammalian iron metabolism. R Eisenstein, Annu Rev Nutr 2000 20 627 662 10.1146/annurev.nutr.20. 1.627 10940348
3. An Iron-Regulated Ferric Reductase Associated with the Absorption of Dietary Iron. AT McKie D Barrow GO Latunde-Dada A Rolfs G Sager E Mudaly M Mudaly C Richardson D Barlow A Bomford,, et al. Science 2001 291 5509 1755 1759 10.1126/science.1057206 11230685 (Pubitemid 32198974)
4. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. MDTCr Fleming MA Su D Foernzler DR Beier WF Dietrich NC Andrews, Nat Genet 1997 16 4 383 386 9241278 (Pubitemid 27323306)
5. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. H Gunshin B Mackenzie UV Berger Y Gunshin MF Romero WF Boron S Nussberger JL Gollan MA Hediger, Nature 1997 388 6641 482 488 10.1038/41343 9242408 (Pubitemid 27328927)
6. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. A Donovan A Brownlie Y Zhou J Shepard SJ Pratt J Moynihan BH Paw A Drejer B Barut A Zapata,, et al. Nature 2000 403 6771 776 781 10.1038/35001596 10693807 (Pubitemid 30111839)
7. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. CD Vulpe YM Kuo TL Murphy L Cowley C Askwith N Libina J Gitschier GJ Anderson, Nat Genet 1999 21 2 195 199 10.1038/5979 9988272 (Pubitemid 29070366)
8. Iron feeding induces ferroportin 1 and hephaestin migration and interaction in rat duodenal epithelium. Ky Yeh M Yeh L Mims J Glass, Am J Physiol Gastrointest Liver Physiol 2009 296 1 55 65 10.1152/ajpgi.90298.2008 18974313
9. Mammalian iron transport. G Anderson C Vulpe, Cellular and Molecular Life Sciences 2009 66 20 3241 3261 10.1007/s00018-009-0051-1 19484405
10. Hepcidin is decreased in TFR2 hemochromatosis. E Nemeth A Roetto G Garozzo T Ganz C Camaschella, Blood 2005 105 4 1803 1806 10.1182/blood-2004-08- 3042 15486069 (Pubitemid 40223705)
11. An alternative model for the binding and release of diferric transferrin by reticulocytes. RCB-MA Woodworth TG Christensen DP Witt RD Comeau, Biochemistry 1982 21 18 4220 4225 10.1021/bi00261a005 7126538 (Pubitemid 13197435)
12. The Steap proteins are metalloreductases. RS Ohgami DR Campagna A McDonald MD Fleming, Blood 2006 108 4 1388 1394 10.1182/blood-2006-02-003681 16609065 (Pubitemid 44232042)
13. Iron Deficiency. RD Baynes TH Bothwell, Annual Review of Nutrition 1990 10 1 133 148 10.1146/annurev.nu.10.070190.001025 2200460
14. Iron deficiency. N Scrimshaw, Sci Am 1991 265 4 46 52 10.1038/scientificamerican1091-46 1745900
15. Risk factors for iron-deficiency anaemia among pregnant women living in rural Vietnam. R Aikawa NC Khan S Sasaki CW Binns, Public Health Nutrition 2006 9 04 443 448 10.1079/PHN2005851 16870016 (Pubitemid 44125263)
16. Prevalence of anemia in Japanese adolescents: 30 years' experience in screening for anemia. MYM Maeda K Yamauchi, Int J Hematol 1999 69 2 75 80 10071454
17. Anemia in older adults. R Woodman L Ferrucci J Guralnik, Current Opinion in Hematology 2005 12 2 123 128 15725902 (Pubitemid 40315696)
18. Modulation of iron transport proteins in human colorectal carcinogenesis. MJ Brookes S Hughes FE Turner G Reynolds N Sharma T Ismail G Berx AT McKie N Hotchin GJ Anderson,, et al. Gut 2006 55 10 1449 1460 10.1136/gut.2006.094060 16641131 (Pubitemid 44476791)
19. Human cell-surface glycoprotein with unusual properties. MBTI Omary J Minowada, Nature 1980 286 5776 888 891 10.1038/286888a0 7412870 (Pubitemid 10010153)
20. Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma. J Boult K Roberts MJ Brookes S Hughes JP Bury SS Cross GJ Anderson R Spychal T Iqbal C Tselepis, Clinical Cancer Research 2008 14 2 379 387 10.1158/1078-0432.CCR-07-1054 18223212 (Pubitemid 351226104)
21. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. P Karihtala Y Soini, APMIS 2007 115 2 81 103 10.1111/j.1600-0463.2007.apm-514.x 17295675 (Pubitemid 46208084)
22. Free radical-lipid interactions and their pathological consequences. C Rice-Evans R Burdon, Progress in Lipid Research 1993 32 1 71 110 10.1016/0163-7827(93)90006-I 8415800 (Pubitemid 23154406)
23. Identification of Small Molecule Inhibitors that Distinguish between Non-Transferrin Bound Iron Uptake and Transferrin-Mediated Iron Transport. JX Brown PD Buckett M Wessling-Resnick, Chemistry & Biology 2004 11 3 407 416 (Pubitemid 39403880)
24. Small-Molecule Screening Identifies the Selanazal Drug Ebselen as a Potent Inhibitor of DMT1-Mediated Iron Uptake. HA Wetli PD Buckett M Wessling-Resnick, Chemistry & Biology 2006 13 9 965 972 (Pubitemid 44375173)
25. Small molecule inhibitors of divalent metal transporter-1. PD Buckett M Wessling-Resnick, Am J Physiol Gastrointest Liver Physiol 2009 296 4 798 804 10.1152/ajpgi.90342.2008 19179627
26. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. FEaWT Turturro Francesco, BMC Cancer 2007 7 96 7 17222331
27. The Small-Molecule Iron Transport Inhibitor Ferristatin/NSC306711 Promotes Degradation of the Transferrin Receptor. L Horonchik M Wessling-Resnick, Chemistry & Biology 2008 15 7 647 653 (Pubitemid 351957905)
28. An Iron Delivery Pathway Mediated by a Lipocalin. J Yang D Goetz JY Li W Wang K Mori D Setlik T Du H Erdjument-Bromage P Tempst R Strong,, et al. Molecular Cell 2002 10 5 1045 1056 10.1016/S1097-2765(02)00710-4 12453413 (Pubitemid 35453824)
29. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. S Ludwiczek I Theurl MU Muckenthaler M Jakab SM Mair M Theurl J Kiss M Paulmichl MW Hentze M Ritter,, et al. Nat Med 2007 13 4 448 454 10.1038/nm1542 17293870 (Pubitemid 46562464)
30. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. JP Liuzzi F Aydemir H Nam MD Knutson RJ Cousins, Proceedings of the National Academy of Sciences 2006 103 37 13612 13617 10.1073/pnas.0606424103 (Pubitemid 44413956)
31. ROS stress in cancer cells and therapeutic implications. H Pelicano D Carney P Huang, Drug Resistance Updates 2004 7 2 97 110 10.1016/j.drup.2004.01. 004 15158766 (Pubitemid 38736063)
32. Reactive Oxygen Species: A Breath of Life or Death? JP Fruehauf FL Meyskens, Clinical Cancer Research 2007 13 3 789 794 10.1158/1078-0432.CCR-06- 2082 17289868 (Pubitemid 46340350)
33. Redox Regulation of Cell Survival. D Trachootham W Lu MA Ogasawara NR-D Valle P Huang, Antioxidants & Redox Signaling 2008 10 8 1343 1374
34. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. A-B Witte K Anestål E Jerremalm H Ehrsson ESJ Arnér, Free Radical Biology and Medicine 2005 39 5 696 703 10.1016/j.freeradbiomed.2005.04.025 16085187 (Pubitemid 41112110)
35. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. ANJ Miyajima K Yoshioka M Tachibana H Tazaki M Murai, Br J Cancer 1997 76 2 206 210 10.1038/bjc.1997.363 9231920 (Pubitemid 27279660)
36. Reactive Oxygen Intermediates Are Involved in the Induction of CD95 Ligand mRNA Expression by Cytostatic Drugs in Hepatoma Cells. H Hug S Strand A Grambihler J Galle V Hack W Stremmel PH Krammer PR Galle, Journal of Biological Chemistry 1997 272 45 28191 28193 10.1074/jbc.272.45.28191 9353266 (Pubitemid 27517754)
37. A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth. S Bonnet SL Archer J Allalunis-Turner A Haromy C Beaulieu R Thompson CT Lee GD Lopaschuk L Puttagunta S Bonnet,, et al. Cancer Cell 2007 11 1 37 51 10.1016/j.ccr.2006.10. 020 17222789 (Pubitemid 46054520)
38. Association of reactive oxygen species levels and radioresistance in cancer stem cells. MCR Diehn NA Lobo T Kalisky MJ Dorie AN Kulp D Qian JS Lam LE Ailles M Wong B Joshua MJ Kaplan I Wapnir FM Dirbas G Somlo C Garberoglio B Paz J Shen SK Lau SR Quake JM Brown IL Weissman MF Clarke, Nature 2009 458 7239 780 783 10.1038/nature07733 19194462
39. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. V Brabec O Novkov Drug Resistance Updates 2006 9 3 111 122 10.1016/j.drup.2006.05.002 16790363 (Pubitemid 44279519)
40. Clioquinol targets zinc to lysosomes in human cancer cells. H Yu Y Zhou SE Lind WQ Ding, Biochem J 2009 417 1 133 139 10.1042/BJ20081421 18764784
41. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. T Efferth, Drug Resistance Updates 2005 8 1-2 85 97 10.1016/j.drup.2005.04.003 15878303 (Pubitemid 40797959)
42. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. JCLH Moore JR Li RL Ren JA McDougall NP Singh CK Chou, Cancer Lett 1995 98 1 83 87 8529210
43. The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy. JM Brown AJ Giaccia, Cancer Research 1998 58 7 1408 1416 9537241 (Pubitemid 28193601)
44. Biological consequences of tumor hypoxia. MVP Höckel, Semin Oncol 2001 28 2 Suppl 8 36 41
45. Hypoxia [mdash] a key regulatory factor in tumour growth. AL Harris, Nat Rev Cancer 2002 2 1 38 47 10.1038/nrc704 11902584 (Pubitemid 37328806)
46. Targeting HIF-1 for cancer therapy. GL Semenza, Nat Rev Cancer 2003 3 10 721 732 10.1038/nrc1187 13130303 (Pubitemid 37328811)
47. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. HMRR Sowter JW Moore PJ Ratcliffe AL Harris, Cancer Res 2003 63 19 6130 6134 14559790 (Pubitemid 37255150)
48. Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis. JDJ Eckard J Wu J Jian Q Yang H Chen M Costa K Frenkel X Huang, Cancer Cell Int 2010 10 28